Eli Lilly’s Breakthrough Obesity Drug Retatrutide Achieves Significant Weight Loss and Blood Sugar Reduction in Late-Stage Diabetes Trial
Eli Lilly’s next-generation obesity drug, retatrutide, has shown promising results in its first late-stage diabetes trial, demonstrating significant reductions in both A1C and weight, with participants experiencing an average weight loss of 16.8%, offering new hope for patients with type 2 diabetes.
Read More